TABLE 2.
Summary of published cases of invasive A. ustus infection
| Patient no., sex/age (reference)a | Underlying disease or conditionb | Diagnosis, infected site | Therapy | Clinical response, outcome | Autopsy findings |
|---|---|---|---|---|---|
| 1, M/50 (2) | Prosthetic valve | Proven, aortic valve prosthesis and mitral valve | Amphotericin B (40 mg/day for 6 weeks); flucytosine (8 g/day) for 10 weeks; valve replacement | Cure, survival | ND |
| 2, M/57 (16) | Excessive skin burns | Probable, skin | Amphotericin B cream | Failure, death | No evidence of disseminated infection |
| 3, M/72 (26) | Cardiac surgery, diabetes mellitus, chronic renal failure | Proven, lung | No antifungal treatment | Failure, death | Multiple infiltrations in lungs, myocardium, kidney, thyroid, and peritoneum |
| 4, F/62 (18) | Liver transplant for end-stage hepatitis C-induced cirrhosis | Proven, skin | Amphotericin B (25 mg every other day); terbinafine cream | Cure, death | No invasive aspergillosis |
| 5, M/9 (1) | AML, aBMT, GvHD | Proven, lung | Amphotericin B (1.5 mg/kg/day) | Failure, death | ND |
| 6, F/64 (15) | COPD, prednisone (60 mg/day) | Probable, skin | Itraconazole (400 mg/day for 2 weeks) | Failure, death | No evidence of disseminated infection |
| 7, F/46 (9) | MDS, aPSCT | Proven, lung | Itraconazole (400 mg/day for 53 days); liposomal amphotericin B (5 mg/kg/day for 12 days) | Failure, death | Multiple infiltrations in lung, myocardium, thyroid, and skin |
| 8, M/38 (PR) | CML, aBMT, GvHD | Proven, lung | Amphotericin B (1 mg/kg/day for 18 days) | Failure, death | Bronchopneumonia; no evidence of disseminated infection |
a
M, male; F, female; PR, present report.
b
AML, acute myeloid leukemia; aBMT, allogeneic BMT; aPSCT, allogeneic peripheral stem cell transplantation; GvHD, graft-versus-host disease; COPD, chronic obstructive pulmonary disease; CML, chronic myeloid leukemia; MDS, myelodysplastic syndrome.
c
ND, not done.